Company Overview and News
2018-09-10 seekingalpha - 1
Discussion: First patient is dosed in Phase 1 clinical trial of Compugen's (CGEN)COM701 indicated as a cancer immunotherapy antibody targeting PVRIG. The safety and tolerability of the drug will be tested in escalating dose of COM701 as both monotherapy and combination therapy in a patient group of 140 with advanced solid tumors. The combination therapy will be administered along with a PD-1 inhibitor.
AZN AMGN OPK TEVJF GILD AZN JNJ CGEN TEVA TEVVF SRPT
A month has gone by since the last earnings report for Sarepta Therapeutics (SRPT - Free Report) . Shares have added about 6.4% in that time frame, outperforming the S&P 500.
ALLY TGI KORS SRPT
CAMBRIDGE, Mass., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a global biopharmaceutical company focused on the discovery and development of precision genetic medicines for the treatment of rare neuromuscular and other rare diseases, will ring Nasdaq’s Opening Bell today in recognition of World Duchenne Awareness Day (WDAD), an observance recognized annually around the world on September 7.
2018-09-05 seekingalpha - 8
While much attention is being riveted on the S&P 500's new all-time high eclipsing the January one, small caps accomplished that in May.
VRTX ECYT VSTM TRXC VKTX ENL CVS LGNDZ RGNX IMMU BIIB LGNYZ REGI HRTX NVTA NBIX ARWR SRPT ICPT VKTXW XLRN FNKO MRTX LGNZZ LGND NVS HEAR LGNXZ NTRA UNH PFE ENDP
CAMBRIDGE, Mass., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted equity awards on August 31, 2018, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to twenty-two individuals hired by Sarepta in August 2018.
Pfizer Inc. (PFE - Free Report) announced that it has terminated two clinical studies evaluating its pipeline candidate, domagrozumab, in patients with Duchenne muscular dystrophy (“DMD”), a progressive muscle degeneration disease. The two studies included a phase II study evaluating the candidate in patients regardless of underlying mutation and another was an open-label extension study.
PFZ SLDB RSG SRPT 500680 PFE PFIZER
Researchers at the University of Texas Southwestern Medical Center used CRISPR gene editing to treat Duchenne muscular dystrophy (DMD) in dogs. Their work was published in the journal Science.
Pfizer terminated two clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD).
Pfizer Inc. PFE, +0.00% is ending ongoing research for a Duchenne muscular dystrophy drug after finding that the evidence "did not support a significant treatment effect," the company said on Thursday. Shares slumped 0.5% premarket, while shares of DMD drugmaker Sarepta Therapeutics Inc. SRPT, +3.53% rose 0.9%. Pfizer plans to keep reviewing trial data "to see if there is a place for this medicine in muscular diseases," said Seng Cheng, senior vice president and chief scientific officer, Pfizer Rare Disease Research Unit.
PFZ SRPT 500680 PFE PFIZER
2018-08-30 biospace - 2
Recently, Milton Packer, a renowned cardiologist at Baylor Scott & White Health, wrote a criticism of the Orphan Drug Act and the resulting problems caused by the biopharma industry. John LaMattina, formerly president of Pfizer Global Research and Development and a current senior partner at PureTech Ventures, responded to the editorial in Forbes. Let’s take a look.
It has been about a month since the last earnings report for Alexandria Real Estate Equities (ARE - Free Report) . Shares have added about 0.7% in that time frame, underperforming the S&P 500.
ARE CNA SRPT URBN
Innovation has always been the mantra when it comes to biotech stocks. And as such, the biotech sector has been the key driver for new medicines and therapies over the last decade or so. But we haven’t seen anything like this before. Gene therapy is quickly becoming the technique du jour for curing orphan and rare diseases.
NITE REGN GILD QURE CELG SRPT KITE BLUE
16h - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
16h - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
18h - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET